🟢 Crispr Therapeutics is trading 4.3% up today as U.S. markets rebound after Fed decision

Crispr Therapeutics is trading 4.3% up at $54.43 as U.S. markets rebound following the Federal Reserve’s September 16 policy decision.

• The Nasdaq is up 1.26% and the S&P 500 is up 0.93%, supporting risk appetite across growth-oriented biotechnology stocks.
• No new company-specific announcement or analyst action clearly explains the September 17 move.
• Recent Morgan Stanley conference commentary highlighted Casgevy growth and several year-end clinical catalysts, including CTX310, CTX611, and zugo-cel data.